AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KSEP 31 min read$NXTC

NextCure, Inc. (NXTC): Entry into a Material Definitive Agreement

NextCure, Inc. (NXTC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement ​ On August 28, 2026, NextCure, Inc. (the "Company") and ARE-8000/9000/10000 Virginia Manor, LLC entered into a Ninth Amendment to the parties’ lease agreement dated January 30, 2019 (the "Amendment") with respect to the Compan

Original reporting
SEC EDGAR 8-K
Published Sep 3, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$NXTC
Neutral
medium confidence
Mentioned
$NXTC
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NXTCNeutralLow
01

Why it matters

The $0.8 M termination fee is a one‑off expense; future rent obligations cease, potentially improving cash flow thereafter.

02

Market read

Primary disclosure of a lease termination; limited trading relevance due to small financial magnitude.

03

What to watch

Potential relocation costs or disruption to R&D activities are not disclosed.

Relevance 6/10Novelty 4/10Timing: filed Sep 3 2026

Background

NextCure disclosed a material definitive agreement terminating its Maryland laboratory lease.

Company-level read

Ticker impact

$NXTCNeutralMedium confidence
Context

NextCure filed an 8‑K reporting a lease termination and a $0.8 M one‑time fee, ending its Maryland lab lease.

Expected impact

Limited short‑term impact; price may dip slightly on the cash expense.

Evidence & confidence

Small termination fee relative to market cap; no change to core operations.

Market effects

Sector

Minimal effect on biotech leasing market; no broader sector impact.

Regional

No significant regional impact.

Global

None

Counterpoint

What could challenge this read

Investors could view the lease exit as a strategic cost‑saving move if the space was underutilized.

Key entities

  • Company
    NextCure, Inc.

    Biopharmaceutical company filing the 8‑K.

  • Landlord
    ARE‑8000/9000/10000 Virginia Manor, LLC

    Counterparty to the lease amendment.

Read at source← All news

Related articles

AUG 12
$NXTCMedAI 8/10

RTW Bio's Avere To Merge With NextCure

RTW Biotech Opportunities said its portfolio company Avere Therapeutics will merge with NextCure Inc. in an all-stock deal expected to close by year-end. The combined firm will trade on Nasdaq as Avere Therapeutics under AVRX. Avere plans $820M in private placements, including $5.9M from Avere, to fund AVR-001 Phase 2b psoriasis, Phase 3 psoriasis, and Phase 2b ulcerative colitis.

rttnews.com3 min
AUG 12
$NXTCMedAI 8/10

Avere Therapeutics to merge with NextCure Inc.

RTW Biotech Opportunities said private portfolio company Avere Therapeutics will go public via an all-stock reverse merger with NextCure Inc., expected by year-end. Avere plans $320 million and $500 million private placements totaling $820 million. The combined company will trade on Nasdaq as Avere Therapeutics, Inc. under ticker AVRX, funding AVR-001 through psoriasis Phase 2b and Phase 3, and ulcerative colitis Phase 2b.

investegate.co.uk4 min
AUG 6
$NXTCMed

NextCure, Inc. (NXTC): Results of Operations and Financial Condition

NextCure, Inc. (NXTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results ​ – Announced Proposed Merger with Avere Therapeutics – Preserving Capital in Support of Merger Closing; Continuing Clinical Transition and Legacy Asset Activities ​ BELTSVILLE, MD –

SEC EDGAR 8-K6 min
JUL 15
$NXTCMedAI 8/10

Top Biotech Gainers: NXTC Soars On Merger Deal, BMGL Moves Past Nasdaq Woes, OTLK Awaits FDA Verdict

Biotech stocks rose Tuesday. NextCure (NXTC) jumped over 200% on a definitive all-stock merger with Avere Therapeutics, expected to close in 2H 2026, with the combined firm trading as AVRX. Basel Medical (BMGL) gained 26% after regaining Nasdaq bid-price compliance. Outlook Therapeutics (OTLK) rose 11% ahead of an FDA decision on July 29, 2026. Other gainers included DYAI, NUWE, ATAI, and QNCX.

rttnews.com2 min